Spironolactone
- Generic Name
- Spironolactone
- Brand Names
- Aldactazide, Aldactone, Carospir, Qaialdo
- Drug Type
- Small Molecule
- Chemical Formula
- C24H32O4S
- CAS Number
- 52-01-7
- Unique Ingredient Identifier
- 27O7W4T232
- Background
Spironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists. It promotes sodium and water excretion and potassium retention. Spironolactone was originally developed purely for this ability before other pharmacodynamic properties of the drug were discovered. It is indicated to treat several conditions, including heart failure, edema, hyperaldosteronism, and hypertension. Off-label uses of spironolactone include hirsutism, female pattern hair loss, and adult acne vulgaris.
Spironolactone was developed in 1957, marketed in 1959, and approved by the FDA on January 21, 1960.
- Indication
Spironolactone is indicated for the treatment of the following conditions:
As spironolactone has antiandrogenic activity, its off-label uses include the treatment of hirsutism, female pattern hair loss, and adult acne vulgaris.
- Associated Conditions
- Edema, Hypertension, Primary Aldosteronism, Primary Hyperaldosteronism, Secondary hyperaldosteronism, Chronic heart failure with reduced ejection fraction (NYHA Class III), Chronic heart failure with reduced ejection fraction (NYHA Class IV), Idiopathic hyperaldosteronism, Refractory Edema
- Associated Therapies
- Perioperative drug treatment, Maintenance therapy
Novel Treatment for Diastolic Heart Failure in Women
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2013-02-18
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 48
- Registration Number
- NCT00206232
- Locations
- 🇺🇸
Baylor College of Medicine Heart Clinic, Houston, Texas, United States
Efficacy of Therapy With the Spironolactone Pills Compared to Minoxidil Lotion in Female Pattern Hair Loss
- Conditions
- Female Pattern Hair Loss
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- University of British Columbia
- Target Recruit Count
- 40
- Registration Number
- NCT00175617
- Locations
- 🇨🇦
UBC Division of Dermatology, Hair Research and Treatment Centre, Vancouver, British Columbia, Canada
Renin-angiotensin-aldosterone System (RAAS), Inflammation, and Post-Operative Atrial Fibrillation (AF)
- Conditions
- Atrial Fibrillation
- Interventions
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2013-03-22
- Lead Sponsor
- Vanderbilt University
- Target Recruit Count
- 455
- Registration Number
- NCT00141778
- Locations
- 🇺🇸
Vanderbilt University, Nashville, Tennessee, United States
Larger Dose of Spironolactone for the Treatment of Patients With Nonischemic Cardiomyopathy
- Conditions
- Heart Failure, Congestive
- First Posted Date
- 2005-08-01
- Last Posted Date
- 2009-07-15
- Lead Sponsor
- Hebei Medical University
- Target Recruit Count
- 200
- Registration Number
- NCT00125437
- Locations
- 🇨🇳
The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
PIE II: Pharmacological Intervention in the Elderly II
- Conditions
- Heart Failure, CongestiveDiastolic Heart Failure
- Interventions
- Drug: Placebo
- First Posted Date
- 2005-07-26
- Last Posted Date
- 2019-02-27
- Lead Sponsor
- Wake Forest University
- Target Recruit Count
- 80
- Registration Number
- NCT00123955
- Locations
- 🇺🇸
Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States
Using the Drug Spironolactone to Test If It Reduces Protein Leakage From the Kidney
- Conditions
- Kidney DiseaseDiabetic NephropathyGlomerulonephritisProteinuria
- First Posted Date
- 2005-03-28
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Melbourne Health
- Target Recruit Count
- 60
- Registration Number
- NCT00106561
- Locations
- 🇦🇺
Department of Nephrology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia
Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function
- Conditions
- Heart DiseasesHeart Failure, CongestiveCardiovascular Diseases
- Interventions
- Drug: Placebo
- First Posted Date
- 2004-10-15
- Last Posted Date
- 2015-03-02
- Lead Sponsor
- Carelon Research
- Target Recruit Count
- 3445
- Registration Number
- NCT00094302
- Locations
- 🇺🇸
Drexel University College of Medicine, Philadelphia, Pennsylvania, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Cardiovascular Research Institute of Dallas, Dallas, Texas, United States
Treatment of Boys With Precocious Puberty
- Conditions
- Precocious Puberty
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- Target Recruit Count
- 80
- Registration Number
- NCT00001202
- Locations
- 🇺🇸
National Institute of Child Health and Human Development (NICHD), Bethesda, Maryland, United States
Phase II Study of the Effect of Leuprolide Acetate and Spironolactone on Insulin Resistance in Hyperandrogenic Women With Polycystic Ovarian Disease or Hyperandrogenism Insulin Resistance Acanthosis Nigricans Syndrome
- Conditions
- Acanthosis NigricansPolycystic Ovary Syndrome
- First Posted Date
- 1999-10-19
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Center for Research Resources (NCRR)
- Registration Number
- NCT00004311
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.